Patent Publication Number: US-8535741-B2

Title: Method and composition for administering bioactive compounds derived from Morinda citrifolia

Description:
RELATED APPLICATIONS 
     This application claims priority to U.S. Patent Application Ser. No. 60/799,793, filed May 12, 2006 and entitled “Method and Composition for Administering Bioactive Compounds Derived from Morinda Citrifolia” and is a divisional application claiming priority to U.S. patent application Ser. No. 11/746,798 filed May 10, 2007, now U.S. Pat. No. 8,025,910 entitled “Method and Compositions for Administering Bioactive Compounds Derived From Morinda Citrifolia.” 
    
    
     BACKGROUND 
     1. Field of Invention 
     This invention relates to a method and composition for providing in various health benefits by administering various bioactive compounds derived from the plant  Morinda cirtrifolia  to individuals. More particularly this invention relates to administering one or more of the following: Pyro-phorbide a, Pheophorbide a, Purpin 7, and/or Pheophorbide Phypolesper all which may be derived from Noni leaf extract, Noni leaf juice, and/or Roast leaf. Moreover, the foregoing formulations result in alleviating pain and inflammation. 
     2. Background 
     People are becoming increasingly more conscientious of their health. With a variety of deadly diseases and ailments threatening the public health each year, efforts to find treatments and medications that treat and prevent disease are ongoing. Moreover, studies show that comprehensive, novel early prevention and detection strategies increase healthy life potential. 
     SUMMARY AND OBJECTS OF THE INVENTION 
     Some embodiments of this invention relate to methods and compositions for providing various health benefits by administering bioactive compounds derived from the plant  Morinda cirtrifolia  to individuals. 
     Some embodiments relate to using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf to inhibit the following: HMG-CoA Reductase; Phosphodiesterases (3 and 4) PDE3 and PDE4; 5-Lipoxygenase (LOX) and 15-LOX; Xanthine Oxidase (X0); Gamma Amino Butyric Acid (GABA) and the growth of the second most common human skin cancer cell line. 
     Some embodiments relate to administering one or more of the following: Pyro-phorbide a, Pheophorbide a, Purpin 7, and/or Pheophorbide Phypolesper all which may be derived from Noni leaf extract, Noni leaf juice, and/or Roast leaf. 
     Some embodiments result in alleviating pain and inflammation. 
    
    
     
       BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS 
       The objects and features of the present invention will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. Understanding that these drawings depict only typical embodiments of the invention and are, therefore, not to be considered limiting of its scope, the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which: 
         FIG. 1  shows an example of a concentration-response curve for inhibition of growth in A431 human tumor cell line treated with Leaf Extract; 
         FIG. 2  shows an example of a concentration-response curve for inhibition of growth in A431 human tumor cell line treated with Leaf Juice; and 
         FIG. 3  shows an example of a concentration-response curve for inhibition of growth in A431 human tumor cell line treated with Leaf Roast. 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     It will be readily understood that the components of the present invention, as generally described herein, could be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of embodiments of the compositions and methods of the present invention is not intended to limit the scope of the invention, as claimed, but is merely representative of the presently preferred embodiments of the invention. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope. 
     This invention relates to a method and composition for providing in various health benefits by administering various bioactive compounds derived from the plant  Morinda cirtrifolia  to individuals. This invention relates to using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf to inhibit the following: HMG-CoA Reductase; Phosphodiesterases (3 and 4) PDE3 and PDE4; 5-Lipoxygenase (LOX) and 15-LOX; Xanthine Oxidase (X0); Gamma Amino Butyric Acid (GABA) and the growth of the second most common human skin cancer cell line. More particularly this invention relates to administering one or more of the following: Pyro-phorbide a, Pheophorbide a, Purpin 7, and/or Pheophorbide Phypolesper all which may be derived from Noni leaf extract, Noni leaf juice, and/or Roast leaf. Moreover, the foregoing formulations result in alleviating pain and inflammation. 
     General Description of the  Morinda citrifolia  L. Plant 
     The Indian Mulberry or  Morinda citrifolia  plant, known scientifically as  Morinda Citrifolia  L. (“ Morinda citrifolia ”), is a shrub or small tree up to 10 m in height. The leaves are oppositely arranged with an elliptic to ovate form. The small white flowers are contained in a fleshy, globose, head like cluster. The fruits are large, fleshy, and ovoid. At maturity, they are creamy white and edible, but have an unpleasant taste and odor. The plant is native to Southeast Asia and has spread in early times to a vast area from India to eastern Polynesia. It grows randomly in the wild, and it has been cultivated in plantations and small individual growing plots. The  Morinda citrifolia  flowers are small, white, three to five lobed, tubular, fragrant, and about 1.25 cm long. The flowers develop into compound fruits composed of many small drupes fused into an ovoid, ellipsoid or roundish, lumpy body, with waxy, white, or greenish-white or yellowish, semi-translucent skin. The fruit contains “eyes” on its surface, similar to a potato. The fruit is juicy, bitter, dull-yellow or yellowish-white, and contains numerous red-brown, hard, oblong-triangular, winged 2-celled stones, each containing four seeds. When fully ripe, the fruit has a pronounced odor like rancid cheese. Although the fruit has been eaten by several nationalities as food, the most common use of the  Morinda citrifolia  plant has traditionally been as a red and yellow dye source. 
     The  Morinda citrifolia  plant is rich in natural ingredients. Those ingredients that have been discovered include from the leaves: alanine, anthraquinones, arginine, ascorbic acid, aspartic acid, calcium, beta carotene, cysteine, cystine, glycine, glutamic acid, glycosides, histidine, iron, leucine, isoleucine, methionine, niacin, phenylalanine, phosphorus, proline, resins, riboflavin, serine, beta sitosterol, thiamine, threonine, tryptophan, tyrosine, ursolic acid, and valine; from the flowers: acacetin 7 o beta d (+) glucopyranoside, 5,7 dimethyl apigenin 4′ o beta d(+) galactopyranoside, and 6,8 dimethoxy 3 methylanthraquinone 1 o beta rhamnosyl glucopyranoside; from the fruit: acetic acid, asperuloside, butanoic acid, benzoic acid, benzyl alcohol, 1 butanol, caprylic acid, decanoic acid, (E) 6 dodeceno gamma lactone, (Z,Z,Z) 8,11,14 eicosatrienoic acid, elaidic acid, ethyl decanoate, ethyl hexanoate, ethyl octanoate, ethyl palmitate, (Z) 6 (ethylthiomethyl)benzene, eugenol, glucose, heptanoic acid, 2 heptanone, hexanal, hexanamide, hexanedioic acid, hexanoic acid (hexoic acid), 1 hexanol, 3 hydroxy 2 butanone, lauric acid, limonene, linoleic acid, 2 methylbutanoic acid, 3 methyl 2 buten 1 ol, 3 methyl 3 buten 1 ol, methyl decanoate, methyl elaidate, methyl hexanoate, methyl 3 methylthio propanoate, methyl octanoate, methyl oleate, methyl palmitate, 2 methylpropanoic acid, 3 methylthiopropanoic acid, myristic acid, nonanoic acid, octanoic acid (octoic acid), oleic acid, palmitic acid, potassium, scopoletin, undecanoic acid, (Z,Z) 2,5 undecadien 1 ol, and vomifol; from the roots: anthraquinones, asperuloside (rubichloric acid), damnacanthal, glycosides, morindadiol, morindine, morindone, mucilaginous matter, nor damnacanthal, rubiadin, rubiadin monomethyl ether, resins, soranjidiol, sterols, and trihydroxymethyl anthraquinone monomethyl ether; from the root bark: alizarin, chlororubin, glycosides (pentose, hexose), morindadiol, morindanigrine, morindine, morindone, resinous matter, rubiadin monomethyl ether, and soranjidiol; from the wood: anthragallol 2,3 dimethylether; from the tissue culture: damnacanthal, lucidin, lucidin 3 primeveroside, and morindone 6beta primeveroside; from the plant: alizarin, alizarin alpha methyl ether, anthraquinones, asperuloside, hexanoic acid, morindadiol, morindone, morindogenin, octanoic acid, and ursolic acid. 
     Processing  Morinda citrifolia  Leaves 
     The leaves of the  Morinda citrifolia  plant are one possible component of the  Morinda citrifolia  plant that may be present in some compositions of the present invention. For example, some compositions comprise leaf extract and/or leaf juice as described further herein. Some compositions comprise a leaf serum that is comprised of both leaf extract and fruit juice obtained from the  Morinda citrifolia  plant. Some compositions of the present invention comprise leaf serum and/or various leaf extracts as incorporated into a nutraceutical product (“nutraceutical” herein referring to any drug or product designed to improve the health of living organisms such as human beings or mammals). 
     In some embodiments of the present invention, the  Morinda citrifolia  leaf extracts are obtained using the following process. First, relatively dry leaves from the  Morinda citrifolia  L. plant are collected, cut into small pieces, and placed into a crushing device—preferably a hydraulic press—where the leaf pieces are crushed. In some embodiments, the crushed leaf pieces are then percolated with an alcohol such as ethanol, methanol, ethyl acetate, or other alcohol-based derivatives using methods known in the art. Next, in some embodiments, the alcohol and all alcohol-soluble ingredients are extracted from the crushed leaf pieces, leaving a leaf extract that is then reduced with heat to remove all the liquid therefrom. The resulting dry leaf extract will herein be referred to as the “primary leaf extract.” 
     In some embodiments of the present invention, the primary leaf extract is pasteurized to at least partially sterilize the extract and destroy objectionable organisms. The primary leaf extract is pasteurized preferably at a temperature ranging from 70 to 80 degrees Celsius and for a period of time sufficient to destroy any objectionable organisms without major chemical alteration of the extract. Pasteurization may also be accomplished according to various radiation techniques or methods. 
     In some embodiments of the present invention, the pasteurized primary leaf extract is placed into a centrifuge decanter where it is centrifuged to remove or separate any remaining leaf juice therein from other materials, including chlorophyll. Once the centrifuge cycle is completed, the leaf extract is in a relatively purified state. This purified leaf extract is then pasteurized again in a similar manner as discussed above to obtain a purified primary leaf extract. 
     Preferably, the primary leaf extract, whether pasteurized and/or purified, is further fractionated into two individual fractions: a dry hexane fraction, and an aqueous methanol fraction. This is accomplished preferably via a gas chromatograph containing silicon dioxide and CH2C12-MeOH ingredients using methods well known in the art. In some embodiments of the present invention, the methanol fraction is further fractionated to obtain secondary methanol fractions. In some embodiments, the hexane fraction is further fractionated to obtain secondary hexane fractions. 
     One or more of the leaf extracts, including the primary leaf extract, the hexane fraction, methanol fraction, or any of the secondary hexane or methanol fractions may be combined with the fruit juice of the fruit of the  Morinda citrifolia  plant to obtain a leaf serum (the process of obtaining the fruit juice to be described further herein). In some embodiments, the leaf serum is packaged and frozen ready for shipment; in others, it is further incorporated into a nutraceutical product as explained herein. 
     Processing  Morinda citrifolia  Fruit 
     Some embodiments of the present invention include a composition comprising fruit juice of the  Morinda citrifolia  plant. Because the  Morinda citrifolia  fruit is for all practical purposes inedible, the fruit must be processed in order to make it palatable for human consumption and included in the compositions of the present invention. Processed  Morinda citrifolia  fruit juice can be prepared by separating seeds and peels from the juice and pulp of a ripened  Morinda citrifolia  fruit; filtering the pulp from the juice; and packaging the juice. Alternatively, rather than packaging the juice, the juice can be immediately included as an ingredient in another product, frozen or pasteurized. In some embodiments of the present invention, the juice and pulp can be pureed into a homogenous blend to be mixed with other ingredients. Other processes include freeze drying the fruit and juice. The fruit and juice can be reconstituted during production of the final juice product. Still other processes may include air drying the fruit and juices prior to being masticated. 
     In a currently preferred process of producing  Morinda citrifolia  fruit juice, the fruit is either hand picked or picked by mechanical equipment. The fruit can be harvested when it is at least one inch (2-3 cm) and up to 12 inches (24-36 cm) in diameter. The fruit preferably has a color ranging from a dark green through a yellow-green up to a white color, and gradations of color in between. The fruit is thoroughly cleaned after harvesting and before any processing occurs. 
     The fruit is allowed to ripen or age from 0 to 14 days, but preferably for 2 to 3 days. The fruit is ripened or aged by being placed on equipment so that the fruit does not contact the ground. The fruit is preferably covered with a cloth or netting material during aging, but the fruit can be aged without being covered. When ready for further processing the fruit is light in color, such as a light green, light yellow, white or translucent color. The fruit is inspected for spoilage or for excessive green color and firmness. Spoiled and hard green fruit is separated from the acceptable fruit. 
     The ripened and aged fruit is preferably placed in plastic lined containers for further processing and transport. The containers of aged fruit can be held from 0 to 30 days, but preferably the fruit containers are held for 7 to 14 days before processing. The containers can optionally be stored under refrigerated conditions prior to further processing. The fruit is unpacked from the storage containers and is processed through a manual or mechanical separator. The seeds and peel are separated from the juice and pulp. 
     The juice and pulp can be packaged into containers for storage and transport. Alternatively, the juice and pulp can be immediately processed into a finished juice product. The containers can be stored in refrigerated, frozen, or room temperature conditions. The  Morinda citrifolia  juice and pulp are preferably blended in a homogenous blend, after which they may be mixed with other ingredients, such as flavorings, sweeteners, nutritional ingredients, botanicals, and colorings. The finished juice product is preferably heated and pasteurized at a minimum temperature of 181° F. (83° C.) or higher up to 212° F. (100° C.). Another product manufactured is  Morinda citrifolia  puree and puree juice, in either concentrate or diluted form. Puree is essentially the pulp separated from the seeds and is different than the fruit juice product described herein. 
     The product is filled and sealed into a final container of plastic, glass, or another suitable material that can withstand the processing temperatures. The containers are maintained at the filling temperature or may be cooled rapidly and then placed in a shipping container. The shipping containers are preferably wrapped with a material and in a manner to maintain or control the temperature of the product in the final containers. 
     The juice and pulp may be further processed by separating the pulp from the juice through filtering equipment. The filtering equipment preferably consists of, but is not limited to, a centrifuge decanter, a screen filter with a size from 1 micron up to 2000 microns, more preferably less than 500 microns, a filter press, a reverse osmosis filtration device, and any other standard commercial filtration devices. The operating filter pressure preferably ranges from 0.1 psig up to about 1000 psig. The flow rate preferably ranges from 0.1 g.p.m. up to 1000 g.p.m., and more preferably between 5 and 50 g.p.m. The wet pulp is washed and filtered at least once and up to 10 times to remove any juice from the pulp. The resulting pulp extract typically has a fiber content of 10 to 40 percent by weight. The resulting pulp extract is preferably pasteurized at a temperature of 181° F. (83° C.) minimum and then packed in drums for further processing or made into a high fiber product. 
     Processing  Morinda citrifolia  Seeds 
     Some  Morinda citrifolia  compositions of the present invention include seeds from the  Morinda citrifolia  plant. In some embodiments of the present invention,  Morinda citrifolia  seeds are processed by pulverizing them into a seed powder in a laboratory mill. In some embodiments, the seed powder is left untreated. In some embodiments, the seed powder is further defatted by soaking and stirring the powder in hexane—preferably for 1 hour at room temperature (Drug:Hexane—Ratio 1:10). The residue, in some embodiments, is then filtered under vacuum, defatted again (preferably for 30 minutes under the same conditions), and filtered under vacuum again. The powder may be kept overnight in a fume hood in order to remove the residual hexane. 
     Still further, in some embodiments of the present invention, the defatted and/or untreated powder is extracted, preferably with ethanol 50% (m/m) for 24 hours at room temperature at a drug solvent ratio of 1:2. 
     Processing  Morinda citrifolia  Oil 
     Some embodiments of the present invention may comprise oil extracted from the  Morinda Citrifolia  plant. The method for extracting and processing the oil is described in U.S. patent application Ser. No. 09/384,785, filed on Aug. 27, 1999 and issued as U.S. Pat. No. 6,214,351 on Apr. 10, 2001, which is incorporated by reference herein. The  Morinda citrifolia  oil typically includes a mixture of several different fatty acids as triglycerides, such as palmitic, stearic, oleic, and linoleic fatty acids, and other fatty acids present in lesser quantities. In addition, the oil preferably includes an antioxidant to inhibit spoilage of the oil. Conventional food grade antioxidants are preferably used. 
     Compositions and Their Use 
     This invention relates to a method and composition for providing in various health benefits by administering various bioactive compounds derived from the plant  Morinda cirtrifolia  to individuals. This invention relates to using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf to inhibit the following: HMG-CoA Reductase; Phosphodiesterases (3 and 4) PDE3 and PDE4; 5-Lipoxygenase (LOX) and 15-LOX; Xanthine Oxidase (X0); Gamma Amino Butyric Acid (GABA) and the growth of the second most common human skin cancer cell line. More particularly this invention relates to administering one or more of the following: Pyro-phorbide a, Pheophorbide a, Purpin 7, and/or Pheophorbide Phypolesper all which may be derived from Noni leaf extract, Noni leaf juice, and/or Roast leaf. Moreover, the foregoing formulations result in alleviating pain and inflammation. 
     Compositions of the present invention may comprise any of a number of  Morinda citrifolia  components such as: leaf extract, leaf juice, leaf serum, fruit juice, fruit pulp, pulp extract, puree, seeds (whether defatted or untreated), and oil. Compositions of the present invention may also include various other ingredients. Examples of other ingredients include, but are not limited to: artificial flavoring, other natural juices or juice concentrates such as a natural grape juice concentrate or a natural blueberry juice concentrate; carrier ingredients; and others as will be further explained herein. 
     Any compositions having the leaf extract from the  Morinda citrifolia  leaves, may comprise one or more of the following: the primary leaf extract, the hexane fraction, methanol fraction, the secondary hexane and methanol fractions, the leaf serum, or the nutraceutical leaf product. 
     In some embodiments of the present invention, active ingredients or compounds of  Morinda citrifolia  components may be extracted out using various procedures and processes commonly known in the art. For instance, the active ingredients may be isolated and extracted out using alcohol or alcohol-based solutions, such as methanol, ethanol, and ethyl acetate, and other alcohol-based derivatives using methods known in the art. These active ingredients or compounds may be isolated and further fractioned or separated from one another into their constituent parts. Preferably, the compounds are separated or fractioned to identify and isolate any active ingredients that might help to prevent disease, enhance health, or perform other similar functions. In addition, the compounds may be fractioned or separated into their constituent parts to identify and isolate any critical or dependent interactions that might provide the same health-benefiting functions just mentioned. 
     Any components and compositions of  Morinda citrifolia  may be further incorporated into a nutraceutical product (again, “nutraceutical” herein referring to any drug or product designed to improve the health of living organisms such as human beings or mammals). Examples of nutraceutical products may include, but are not limited to: intravenous products, topical dermal products, wound healing products, skin care products, hair care products, beauty and cosmetic products (e.g., makeup, lotions, etc.), burn healing and treatment products, first-aid products, antibacterial products, lip balms and ointments, bone healing and treatment products, meat tenderizing products, anti-inflammatory products, eye drops, deodorants, antifungal products, arthritis treatment products, muscle relaxers, toothpaste, and various nutraceutical and other products as may be further discussed herein. 
     The compositions of the present invention may be formulated into any of a variety of embodiments, including oral compositions, topical dermal solutions, intravenous solutions, and other products or compositions. 
     Oral compositions may take the form of, for example, tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, syrups, or elixirs. Compositions intended for oral use may be prepared according to any method known in the art, and such compositions may contain one or more agents such as sweetening agents, flavoring agents, coloring agents, and preserving agents. They may also contain one or more additional ingredients such as vitamins and minerals, etc. Tablets may be manufactured to contain one or more  Morinda citrifolia  components in admixture with non-toxic, pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, granulating and disintegrating agents, binding agents, and lubricating agents. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be used. 
     Aqueous suspensions may be manufactured to contain the  Morinda citrifolia  components in admixture with excipients suitable for the manufacture of aqueous suspensions. Examples of such excipients include, but are not limited to: suspending agents such as sodium carboxymethyl-cellulose, methylcellulose, hydroxy-propylmethycellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as a naturally-occurring phosphatide like lecithin, or condensation products of an alkylene oxide with fatty acids such as polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols such as heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitor monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides such as polyethylene sorbitan monooleate. 
     Typical sweetening agents may include, but are not limited to: natural sugars derived from corn, sugar beets, sugar cane, potatoes, tapioca, or other starch-containing sources that can be chemically or enzymatically converted to crystalline chunks, powders, and/or syrups. Also, sweeteners can comprise artificial or high-intensity sweeteners, some of which may include aspartame, sucralose, stevia, saccharin, etc. The concentration of sweeteners may be between from 0 to 50 percent by weight of the  Morinda citrifolia  composition, and more preferably between about 1 and 5 percent by weight. 
     Typical flavoring agents can include, but are not limited to, artificial and/or natural flavoring ingredients that contribute to palatability. The concentration of flavors may range, for example, from 0 to 15 percent by weight of the  Morinda citrifolia  composition. Coloring agents may include food-grade artificial or natural coloring agents having a concentration ranging from 0 to 10 percent by weight of the  Morinda citrifolia  composition. 
     Typical nutritional ingredients may include vitamins, minerals, trace elements, herbs, botanical extracts, bioactive chemicals, and compounds at concentrations from 0 to 10 percent by weight of the  Morinda citrifolia  composition. Examples of vitamins include, but are not limited to, vitamins A, B1 through B12, C, D, E, Folic Acid, Pantothenic Acid, Biotin, etc. Examples of minerals and trace elements include, but are not limited to, calcium, chromium, copper, cobalt, boron, magnesium, iron, selenium, manganese, molybdenum, potassium, iodine, zinc, phosphorus, etc. Herbs and botanical extracts may include, but are not limited to, alfalfa grass, bee pollen, chlorella powder, Dong Quai powder, Ecchinacea root, Gingko Biloba extract, Horsetail herb, Indian mulberry, Shitake mushroom, spirulina seaweed, grape seed extract, etc. Typical bioactive chemicals may include, but are not limited to, caffeine, ephedrine, L-carnitine, creatine, lycopene, etc. 
     The ingredients to be utilized in a topical dermal product may include any that are safe for internalizing into the body of a mammal and may exist in various forms, such as gels, lotions, creams, ointments, etc., each comprising one or more carrier agents. The ingredients or carrier agents incorporated into systemically (e.g., intravenously) administered compositions may also comprise any known in the art. 
     In one exemplary embodiment, a  Morinda citrifolia  composition of the present invention comprises one or more of a processed  Morinda citrifolia  component present in an amount by weight between about 0.01 and 100 percent by weight, and preferably between 0.01 and 95 percent by weight. Several embodiments of formulations are included in U.S. Pat. No. 6,214,351, issued on Apr. 10, 2001. However, these compositions are only intended to be exemplary, as one ordinarily skilled in the art will recognize other formulations or compositions comprising the processed  Morinda citrifolia  product. 
     In another exemplary embodiment, the internal composition comprises the ingredients of: processed  Morinda citrifolia  fruit juice or puree juice present in an amount by weight between about 0.1-80 percent; processed  Morinda citrifolia  oil present in an amount by weight between about 0.1-20 percent; and a carrier medium present in an amount by weight between about 20-90 percent.  Morinda citrifolia  puree juice or fruit juice may also be formulated with a processed  Morinda citrifolia  dietary fiber product present in similar concentrations. 
     EXAMPLES 
     The following examples illustrate some of the embodiments of the invention. These examples are not intended to be limiting in any way, but are merely illustrative of benefits, advantages, and remedial effects of some embodiments of the  Morinda citrifolia  compositions of the present invention. 
     Example 1 
     Noni Leaf Juice 
     In one example, the effects of  Morinda Citrifolia  leaf juice on 5-LOX and 15-LOX, HMG-CoA, PDE3 and PDE4, XO and GABA were studied.  Morinda Citrifolia  leaf juice was administered to rabbits, rats, humans and bovines at various concentration dosages. Inhibition of 5-LOX and 15-LOX was observed in both rabbits and humans, respectively. Inhibition of HMG-CoA Reductase was observed in rats. Inhibition of PDEs was observed in humans. Inhibition of xanthine oxidase was observed in bovines and inhibition of GABA was observed in rats. The following tables summarize the results of these studies. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Example 1 
               
            
           
           
               
               
               
               
               
            
               
                   
                 Test 
                   
                   
                 Std. 
               
               
                 Enzyme 
                 Animal 
                 No. Samples 
                 % Inhibition 
                 Deviation 
               
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 HMG-CoA Reductase 
                 Rat 
                 2 
                 10%  
                 29 
               
               
                   
                   
                 2 
                 5% 
                 5 
               
               
                   
                   
                 2 
                 1% 
                 −3 
               
               
                 Lipoxygenase 15- 
                 Rabbit 
                 2 
                 10%  
                 111 
               
               
                 LOX 
                   
                 2 
                 5% 
                 102 
               
               
                   
                   
                 2 
                 1% 
                 87 
               
               
                 Lipoxygenase 5- 
                 Human 
                 2 
                 10%  
                 101 
               
               
                 LOX 
                   
                 2 
                 5% 
                 85 
               
               
                   
                   
                 2 
                 1% 
                 41 
               
               
                 Phosphodiesterase 
                 Human 
                 2 
                 10%  
                 71 
               
               
                 PDE3 
                   
                 2 
                 5% 
                 33 
               
               
                   
                   
                 2 
                 1% 
                 8 
               
               
                 Phosphodiesterase 
                 Human 
                 2 
                 10%  
                 94 
               
               
                 PDE4 
                   
                 2 
                 5% 
                 45 
               
               
                   
                   
                 2 
                 1% 
                 17 
               
               
                 Phosphodiesterase 
                 Human 
                 2 
                 10%  
                 41 
               
               
                 PDE5 
                   
                 2 
                 5% 
                 0 
               
               
                   
                   
                 2 
                 1% 
                 6 
               
               
                 Xanthine Oxidase 
                 Bovine 
                 2 
                 10%  
                 33 
               
               
                   
                   
                 2 
                 5% 
                 29 
               
               
                   
                   
                 2 
                 1% 
                 6 
               
               
                 GABA 2 , Agonist Site 
                 Rat 
                 2 
                 10%  
                 105 
               
               
                   
                   
                 2 
                 5% 
                 104 
               
               
                   
                   
                 2 
                 1% 
                 103 
               
               
                   
               
            
           
         
       
     
     Example 2 
     Noni Leaf Extract 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Example 2 
               
            
           
           
               
               
               
               
               
            
               
                   
                 Test 
                   
                 % NLEX in 
                   
               
               
                   
                 Animal 
                 No. Samples 
                 Solution 
                 % Inhibition 
               
               
                   
                   
               
            
           
           
               
               
               
               
               
            
               
                 HMG-CoA 
                   
                   
                   
                   
               
               
                 Reductase 
               
               
                 NLEX-P 
                 rat 
                 2 
                 0.1% 
                 54 
               
               
                   
                   
                 2 
                 0.05%  
                 40 
               
               
                   
                   
                   
                 0.025%  
                 7 
               
               
                 Phophodiestrerase 
               
               
                 PDE3 
               
               
                 NLEX-P 
                 hum 
                 2 
                 0.1% 
                 79 
               
               
                   
                   
                 2 
                 0.05%  
                 69 
               
               
                   
                   
                 2 
                 0.025%  
                 58 
               
               
                 Phophodiestrerase 
               
               
                 PDE4 
               
               
                 NLEX-P 
                 hum 
                 2 
                 0.1% 
                 82 
               
               
                   
                   
                 2 
                 0.5% 
                 69 
               
               
                   
                   
                 2 
                 0.025%  
                 54 
               
               
                 Phophodiestrerase 
               
               
                 PDE5 
               
               
                 NLEX-P 
                 hum 
                 2 
                 0.1% 
                 87 
               
               
                   
                   
                 2 
                 0.05%  
                 84 
               
               
                   
                   
                 2 
                 0.025%  
                 77 
               
               
                   
               
            
           
         
       
     
     Example 2 (above) was based on the following parameters: 
     
       
         
           
               
             
               
                 TABLE 3 
               
               
                   
               
               
                 HMG-CoA Reductase 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 Source: 
                 Wistar Rat liver 
               
               
                 Substrate: 
                 2.504[14C]HMG-CoA 
               
               
                 Vehicle: 
                 1% DMSO 
               
               
                 Pre-Incubation Time/Temp: 
                 15 minutes @ 37° C. 
               
               
                 Incubation Buffer: 
                 100 mM Potassium Phosphate, pH 
               
               
                   
                 7.5, 20 mM G-6-P. 2.5 mM NADP 
               
               
                   
                 10 mM EDTA 5 mM DTT, 14 U G- 
               
               
                   
                 6-P-DH 
               
               
                 Quantitation Method: 
                 Quantitation of [14C]Mevalonate 
               
               
                 Significance Criteria: 
                 &gt;50% of max stimulation or inhibition 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 4 
               
               
                   
               
               
                 Phosphodiesterase PDE3 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 Source: 
                 Human platelets 
               
               
                 Substrate: 
                 1.01/.2M (PH]cAMP + cAMP) 
               
               
                 Vehicle: 
                 1% DMSO 
               
               
                 Pre-Incubation Time/Temp: 
                 15 minutes @ 25° C. 
               
               
                 Incubation Time/Temp: 
                 20 minutes @ 25° C. 
               
               
                 Incubation Buffer: 
                 50 mM Tris-HCL, pH 7.5.5 mM 
               
               
                   
                 MgC12 
               
               
                 Quantitation Method: 
                 Quantitation of (PH) Adenosine 
               
               
                 Significance Criteria: 
                 ≧50% of max stimulation or inhibition 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 5 
               
               
                   
               
               
                 Phosphodiesterase PDE4 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 Source: 
                 Human U937 cells 
               
               
                 Substrate: 
                 1.01 MM (PHicAMP + cAMP) 
               
               
                 Vehicle: 
                 1% DMSO 
               
               
                 Pre-Incubation Time/Temp: 
                 15 minutes @ 25° C. 
               
               
                 Incubation Time/Temp: 
                 20 minutes @ 25° C. 
               
               
                 Incubation Buffer: 
                 50 mM Tris-HCL, pH 7.5.5 mM 
               
               
                   
                 MgC12 
               
               
                 Quantitation Method: 
                 Quantitation of (PH) Adenosine 
               
               
                 Significance Criteria: 
                 ≧50% of max stimulation or inhibition 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 6 
               
               
                   
               
               
                 Phosphodiesterase PDE5 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 Source: 
                 Human platelets 
               
               
                 Substrate: 
                 1.01/zM (PH]cGMP + cGMP) 
               
               
                 Vehicle: 
                 1% DMSO 
               
               
                 Pre-Incubation Time/Temp: 
                 15 minutes @ 25° C. 
               
               
                 Incubation Time/Temp: 
                 20 minutes @ 25° C. 
               
               
                 Incubation Buffer: 
                 50 mM Tris-HCL, pH 7.5.5 mM 
               
               
                   
                 MgC12 
               
               
                 Quantitation Method: 
                 Quantitation of (PH) Guanosine 
               
               
                 Significance Criteria: 
                 &gt;50% of max stimulation or inhibition 
               
               
                   
               
            
           
         
       
     
     Example 3 
     In this next example,  Morinda citrifolia  leaf juice and leaf extract was shown to significantly inhibit the growth of the second most common type of human skin cancer. In this example, assays were performed to detect changes in cell proliferation based on the ability of viable cells to cause alamarBlue to change from non-fluorescent blue to a reduced, fluorescent red form. With the results obtained from the alamarBlue reaction, cell proliferation can be quantified and metabolic activity of viable cells can be examined. Test compounds including  Morinda citrifolia  leaf extract, leaf juice, and roast leaf were tested for their effects on the proliferation of human epidermoid carcinoma cell line-A431 at assay concentrations from 0.01 to 100 μg/ml or 0.0001% to 1% through serial 10-fold dilutions. 
     In summary, it was found that the leaf extract at concentrations between 10 and 100 μg/ml, as well as the leaf juice between 0.1% and 1%, caused significant growth inhibition (&lt;50% of growth) relative to the vehicle-treated control in the tumor cell line—whereas the roast leaf failed to show a significant effect (0.01-100 μg/ml). Significant inhibitory activity was also observed for the concurrently tested standard reference agent, Mitomycin, at &lt;10 p.M. Consequently, semi-quantitative determinations of estimated LC 50  (50% inhibition concentration), TGI (total growth inhibition) and LC 50  (50% lethal concentration) by nonlinear regression analysis were calculated. Following is a description of the materials, equipment, and methods used in the assay, as well as tables summarizing the results. 
     Test Substances and Concentrations. 
       Morinda citrifolia  leaf extract, leaf juice, and roast leaf were provided by Tahitian Noni International, Inc. for in vitro anti-tumor studies. The  Morinda citrifolia  compounds were dissolved in sterile distilled water and then diluted with sterile distilled water to obtain initial working solutions of 10000, 1000, 100, 10, and 1 μg/ml for the leaf extract and roast leaf, as well as 100, 10, 1, 0.1 and 0.01% for the leaf juice. In testing, 100-fold dilution was made in culture media to get final assay concentrations of 100, 10, 1, 0.1 and 0.01 μg/ml, and 1, 0.1, 0.01, 0.001 and 0.0001%, respectively. 
     Cell Line and Culture Media. 
     The tumor cell line, A431 (human epidermoid carcinoma), obtained from American Type Culture Collection (ATCC CRL-1555), was incubated in an air atmosphere of 5% CO 2  at 37° C. The culture medium was used with Dulbecco&#39;s Modified Eagle&#39;s medium, 90%; Fetal Bovine Serum, 10% and supplemented with 1% Antibiotic-Antimycotic. 
     Chemicals. 
     The following chemicals were used in the assay: AlamarBlue (Biosource, USA), Antibiotic-Antimycotic (GIBCO BRL, USA), Dulbecco&#39;s Modified Eagle&#39;s Medium (GIBCO BRL, USA), Fetal Bovine Serum (HyClone, USA), and Mitomycin (Kyowa, Japan). 
     Equipment. 
     The following equipment was used in the assay: CO 2  Incubator (Form a Scientific Inc., USA), Centrifuge 5810R (Eppendorf, Germany), Hemacytometer (Hausser Scientific Horsham, USA), Inverted Microscope CK-40 (Olympus, Japan), System Microscope E-400 (Nikon, Japan), Spectrafluor Plus (Tecan, Austria), and Vertical Laminar Flow (Tsao Hsin, R.O.C.). 
     Methods. 
     The anti-proliferation for the test substances was evaluated. Aliquots of 100 pl of cell suspension (about 3×10 3 /well) were placed in 96-well microtiter plates in an atmosphere of 5% CO 2  at 37° C. After 24 hours, 100 pl of growth medium and 2 pl of test solution, Mitomycin or vehicle (distilled water) were added respectively per well in duplicate for an additional 72-hour incubation. Two test compounds, leaf extract and roast leaf, were evaluated at concentrations of 100, 10, 1, 0.1 and 0.01 pg/ml. The other compound, leaf juice, was evaluated at concentrations of 1, 0.1, 0.01, 0.001 and 0.0001%. At the end of incubation, 20 pl of 90% alamarBlue reagent was added to each well for another 6-hour incubation before detection of cell viability by fluorescent intensity. Fluorescent intensity was measured using a Spectrafluor Plus plate reader with excitation at 530 nm and demission at 590 nm. 
     IC 50 , TGI, and LC 50  values were then determined. IC 50  (50% Inhibition Concentration) is the test compound concentration where the increase from time o  in the number or mass of treated cells was only 50% as much as the corresponding increase in the vehicle-control at the end of the experiment. TGI (Total Growth Inhibition) is the test compound concentration where the number or mass of treated cells at the end of the experiment was equal to that at time 0 . LC 50  (50% Lethal Concentration) is the test compound concentration where the number or mass of treated cells at the end of the experiment was half that at time 0 . The measured results were calculated by the following formula:
 
 PG (%)=100×(Mean  F   test −Mean  F   time0 ) / (Mean  F   ctr l −Mean  F   time0 )
 
     If (Mean F test −Mean F time0 ) &lt;0 , then
 
 PG (%)−100×(Mean  F   test −Mean  F   time0 )/(Mean  F   time0 −Mean  F   blank )
 
     Where: PG=percent growth; Mean F time0 =The average of 2 measured fluorescent intensities of reduced alamarBlue at the time just before exposure of cells to the test substance; Mean F test =The average of 2 measured fluorescent intensities of alamarBlue after 72-hour exposure of cells to the test substance; Mean F ctrl =The average of 2 measured fluorescent intensities of alamarBlue after 72-hour incubation without the test substance; and Mean F blank =The average of 2 measured fluorescent intensities of alamarBlue in medium without cells after 72-hour incubation. 
     A decrease of 50% or more (≧50%) in fluorescent intensity relative to the vehicle-treated control indicated significant cell growth inhibition, cytostatic or cytotoxic activity, and a semi-quantitative IC 50 , TGI, and LC 50  were then determined by nonlinear regression using GraphPad Prism (GraphPad Software, USA). 
     Results. 
     The following tables summarize the results of the assay. 
     Effect of  Morinda Citrifolia  Test Substances on the Growth of A431 Skin Tumor Cells 
     
       
         
           
               
               
               
               
             
               
                 TABLE 7 
               
             
            
               
                   
               
               
                   
                   
                   
                 Percent Grown 
               
               
                   
                   
                   
                 (Mean = SEM, n = 2) 
               
               
                 Test 
                 Assay 
                   
                 Concentration (111/m1) 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 Substance 
                 Name 
                 A Blank 
                 Time 0 
                   u Vehicle 
                 100 
                 10 
                 1 
                 0.1 
                 0.01 
               
               
                   
               
               
                 Leaf Extract 
                 Skin 
                 −100 
                 0 
                 100 
                 46 +/− 1 
                 72 +/− 5 
                 89 +/− 1 
                 88 +/− 3 
                 101 +/− 7 
               
               
                 Roast Leaf 
                 Skin 
                 −100 
                 0 
                 100 
                 72 +/− 5 
                 79 +/− 4 
                 87 +/− 2 
                 91 +/− 6 
                  99 +/− 5 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
             
               
                 TABLE 8 
               
             
            
               
                   
               
               
                   
                   
                   
                 Percent Grown 
               
               
                 Test 
                 Assay 
                   
                 Concentration (%) 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 Substance 
                 Name 
                 Blank 
                 Time 0 
                 Vehicle 
                 1 
                 0.1 
                 0.01 
                 0.001 
                 0.001 
               
               
                   
               
               
                 Leaf Juice 
                 Skin 
                 −100 
                 0 
                 100 
                 74 +/− 2 
                 83 +/− 2 
                 77 +/− 2 
                 83 +/− 2 
                 94 +/− 1 
               
               
                 Roast Leaf 
                 Skin 
                 −100 
                 0 
                 100 
                 72 +/− 5 
                 79 +/− 4 
                 87 +/− 2 
                 91 +/− 6 
                 94 +/− 5 
               
               
                   
               
            
           
         
       
     
                                 TABLE 9                              Percent Grown       Test   Assay       Concentration (ttM)                                                     Substance   Name   Blank   Time 0   Vehicle   10   1   0.1   0.01   0.001               Mitomycin   Skin   −100   0   100   97 +/− 0   35 +/− 8   7 +/− 3   82 +/− 3   101 +/− 5                    
A decrease of 50% or more (≧50%) in fluorescent intensity relative to vehicle-treated control indicates significant growth inhibition, cytostatic or cytotoxic activity.
 
As utilized in tables 7-10, the following terms mean:
 
Blank: In duplicate, average fluorescent intensity of alamarBlue in medium without cells after 3-day incubation period relative to time d  (transformed and recorded as −100%).
 
Time 0 : In duplicate, average fluorescent intensity of alamarBlue in medium just before exposure of cells to test substance (transformed and recorded as 0%).
 
Vehicle: In duplicate, average fluorescent intensity of alamarBlue in medium containing cells and added vehicle after 3-day incubation period relative to time d  (transformed and recorded as 100%).
 
Mso (50% Inhibition Concentration): Test compound concentration where the increase from time d  in the number or mass of treated cells was only 50% as much as the corresponding increase in the vehicle-control at the end of experiment.
 
TGI (Total Growth Inhibition): Test compound concentration where the number or mass of treated cells at the end of experiment was equal to that at timed.
 
LC 50  (50% Lethal Concentration): Test compound concentration where the number or mass of treated cells at the end of experiment was half that at timed.
 
The following figures are concentration-response curves for inhibition of growth in A431 human tumor cell line treated with Leaf Extract, Leaf Juice and Roast Leaf.
 
     IC 50  TG 1  and LC 50  Values of  Morinda Citrifolia  Test Compounds 
     
       
         
           
               
               
               
               
               
             
               
                 TABLE 10 
               
               
                   
               
               
                 Compound 
                 Assay Name 
                 aic50 
                 bTGI 
                 c1_, Cso 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 Leaf Extract 
                 Tumor, Skin 
                 76 
                 μg/ml 
                 &gt;100 
                 μg/ml 
                 &gt;100 
                 μg/ml 
               
            
           
           
               
               
               
               
               
            
               
                 Leaf Juice 
                 Tumor, Skin 
                 0.20% 
                 0.36% 
                 0.65% 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 Roast Leaf 
                 Tumor, Skin 
                 &gt;100 
                 μg/ml 
                 &gt;100 
                 μg/ml 
                 &gt;100 
                 μg/ml 
               
               
                 Mitomycin 
                 Tumor, Skin 
                 0.035 
                 μM 
                 0.19 
                 μM 
                 1.0 
                 μIVI 
               
               
                   
               
            
           
         
       
     
     A semi-quantitative determination of IC 50  TG 1  and LC 50  was carried out by nonlinear regression analysis using GraphPad Prism (GraphPad Software, USA). 
     In summary, some embodiments of the present invention provide using Noni leaf juice and Noni leaf extract to inhibit: HMG-CoA Reductase; PDE3 and PDE4; 5-LOX and 15-LOX; XO; GABA and the growth of the second most common human skin cancer cell line, for the purpose of: alleviating pain and inflammation; treating prostate cancers; lower cholesterol levels; counteracting Diabetes Type II; maintaining the highest possible integrity of cellular interactions in the brain resulting in an undisturbed neural function, (i.e. neuroprotection); ameliorating the effects of asthma and allergies; improving energy; improving insulin secretion; decreasing kidney stone accumulation; alleviating the effects of gout; minimizing convulsions related to epilepsy and other seizure disorders; and providing palliative effects to those addicted to drugs. 
     Example 4 
     Additionally, the squeezed juice from fresh  Morinda citrifolia  leaf was utilized to identify by bio-assay on Adenosine A2A four bio-active compounds which have been isolated and identified to have significant bioactivity. Their structures have been determined by NMR techniques and mass spectrometry and they have been identified as Pyro-phorbide a, Pheoporbide a, Purpin 7, and Pheophorbide Phytolester. The isolation and characterization of the above referenced bioactive compounds provides a significant explanation for the anti-inflammatory and analgesic properties of extracts derived from the  Morinda citrifolia  plant, particularly from the leaf of the plant. 
     The present invention may be embodied in other specific forms without departing from its spirit of essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims, rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.